Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients’ Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study

#2053

Introduction: TGR (% change in tumour volume per month (%/m)) is postulated to be an early radiological biomarker to overcome limitations of RECIST in NETs.

Aim(s): Assessment of the impact of TGR on progression-free survival (PFS).

Materials and methods: Patients (pts) from 7 centres with advanced grade(G) 1/2 NETs from the pancreas (P) or small bowel (SB) initiating systemic treatment (ST) or watch and wait (WW) were eligible. Baseline and follow-up scans were retrospectively reviewed to calculate TGR at first follow-up (TGRfirst) and 3 (+/-1) months of study entry (TGR3m). TGR cut-off using TGRfirst for prediction of 12-month-progression rate (12mPgR) was identified (ROC curve); cut-off was applied to TGR3m and its impact on PFS assessed (Kaplan-Meier/Log-rank/Cox Regression).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Lamarca A

Authors: Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C,

Keywords: tumor growth rate, response, progression-free survival, follow-up, neuroendocrine tumor, prognosis, TGR, RECIST, radiology,